



The existence of cell free DNA in the human circulatory system has been known since the 1950s, however, intensive research in this area has been 
conducted for the last ten years. This review paper brings a short overview of the existing literature concerning the cell free DNA research in various 
clinical fi elds and pathological states and considers the application possibilities of this new analyte in clinical laboratory diagnostics.
At the moment, cell free DNA is most widely used for the purpose of non-invasive prenatal diagnosis of fetal sex or fetal RhD status. The recent disco-
very of epigenetic changes in placental/fetal DNA and the detection of fetal/placental-specifi c RNAs have made it possible to use this technology in 
all pregnancies irrespective of the gender of the fetus. With the application of new techniques such as next generation sequencing, digital PCR and 
mass spectrometry, it is now possible to detect very small amounts of specifi c DNA in the presence of excess of other nonspecifi c nucleic acids. Se-
cond most probable application is in oncology, where detection and monitoring of tumors is now possible by the detection of tumor-derived nucleic 
acids. Third promising fi eld for near future implementation of this analyte is transplantation medicine, where free DNA level could serve as a marker 
of transplant rejection.
Before any further utilization of this new biomarker, pre-analytical and analytical aspects of free DNA analysis remain to be standardized. In the fi eld 
of noninvasive prenatal diagnosis, important ethical, legal and social questions remain to be discussed.
Key words: cell free DNA; cell free fetal DNA; plasma DNA; free DNA; non-invasive prenatal diagnosis; clinical laboratory diagnosis; sex determina-
tion analysis
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Free DNA – new potential analyte in clinical laboratory diagnostics?
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The existence of cell free DNA in the human circu-
latory system has been known since the 1948, 
when Mandel and Matais managed to prove the 
existence of nucleic acids in human plasma (1). This 
great discovery did not attract much attention at 
that time. A paper from 1977, which suggested the 
potential application of the cell free DNA in tumor 
diagnosis and in monitoring the antitumor thera-
py success rate (2), attracted a somewhat bigger 
attention of the scientifi c audience. In 1997, Dennis 
Lo et al. attracted the majority of interest for cell 
free DNA research with their discovery of the free 
fetal DNA presence in maternal blood which 
opened the possibility for free DNA analysis appli-
cation in non-invasive prenatal diagnosis (3).
The term ‘’free DNA’’ refers to the compound of 
DNA fragments detectable in various body fl uids. 
Plasma or serum are most frequently used for that 
purpose, however, the presence of the free DNA 
was detected in urine (4-7), saliva (8,9), feces (10), 
synovial liquid (11), cerebrospinal fl uid (12) and 
peritoneal fl uid (13). Normal concentration of the 
free DNA in healthy individuals varies from 0 to 
100 ng/mL of blood, on average 30 ng/mL (14). Ma-
jority of the free plasma DNA is double-stranded 
and consists of DNA molecules sized 0.18-21 kilo-
base (15). Even though the origin of the free circu-
lating DNA has been researched for the last 30 
years, the exact mechanism of its emergence re-
mains unknown. Most researchers agree that it en-
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ters in the circulation when a cell dies, whether by 
necrosis or apoptosis (15,16), however, there is also 
an opinion that apoptosis and necrosis contribute 
to the emergence of the free DNA only to a lesser 
extent while it predominantly occurs as a conse-
quence of spontaneous release of DNA from the 
living cells (17,18). In the context of free tumor DNA, 
some opinions state that in addition to the tumor 
cells themselves, normal cells which are surround-
ing the tumor also contribute to the level of free 
DNA (15).
The clearance of such molecules has not yet been 
clarifi ed. Experimental studies on animal models 
show that liver, and to a lesser extent kidney, are 
the organs responsible for the elimination of free 
DNA from the organism (19). Clearance analysis of 
free fetal DNA from maternal blood after birth (20) 
shows that free DNA rapidly clears from the organ-
ism (t½=16.3 minutes). Second to blood, the most 
extensively analyzed source of the free DNA is 
urine. Experiments performed in mice and humans 
have shown that the kidney barrier in rodents and 
humans is permeable for DNA molecules large 
enough to be analyzed by standard genetic meth-
ods (7). This has been additionally proven by the 
urinary DNA examination (6) which showed two 
diff erent DNA fractions in urine: the fi rst fraction 
consists of DNA molecules larger than one kilobase 
which mainly originate from the cells found in the 
urinary tract while the second fraction consists of 
molecules sized 150-250 bp (found in urine super-
natant after centrifugation) which at least partially 
enters into the urine from circulation. This has 
opened new possibilities for free DNA analysis since 
the analysis of free urinary DNA has several advan-
tages over free plasma DNA analysis: non-invasive 
sampling, urine as a sample is less infectious, easier 
access to a large sample quantity, extraction of DNA 
from urine is analytically less demanding due to the 
signifi cantly smaller concentration of proteins.
Healthy people have a very low level of free DNA 
in circulatory system because dead cells are eff ec-
tively removed from the organism by phagocyto-
sis. An increased level of free DNA in the circulato-
ry system shows either its increased release from 
cells or its decreased removal effi  ciency from the 
organism or both.
Autoimmune diseases
For many years, free DNA research has been fo-
cused on examining the level of free DNA in auto-
immune diseases like rheumatoid arthritis (2,11), 
systemic lupus erythematosus (21-24), systemic 
sclerosis (25) and primary Sjögren’s syndrome (26).
It has been known for some time that DNA struc-
tures that are targeted by auto-antibodies play a 
central role in systemic lupus erythematosus (SLE) 
and that DNA-antibody complexes in the circula-
tion are one of the hallmarks of SLE. Investigating 
whether and to what degree fl uctuations in free 
plasma DNA levels in patients with SLE might cor-
respond to disease severity was the goal of investi-
gations over the past 50 years (21-24). The most re-
cent data seem to exclude measuring free plasma 
DNA as an inexpensive, simple and quick tool to 
assess disease activity in patients with SLE (24,25). 
Further studies on a larger patient population are 
still needed to confi rm these results.
In case of rheumatoid arthritis, Leon et al. (11) have 
discovered higher concentrations of free DNA in 
both plasma and synovial liquid than in healthy 
subjects while the increasing intensity correlated 
with the symptom severity and the level of the tis-
sue damage. Unlike them, Mosca et al. (26) did not 
establish the signifi cant diff erence in free DNA 
concentration in patients with systemic sclerosis 
(SS) and in healthy subjects, but based on the free 
DNA level they could make a diff erence between 
patients with active disease and those with the in-
active one.
Galeazzi et al. (27) have analyzed both circulating 
free DNA and DNA extracted from nucleated blood 
cells in systematic sclerosis and in lupus patients 
and, by using gel electrophoresis, were able to de-
fi ne the pattern of the DNA, instead of simply dos-
ing its amount in the circulation. They found that 
SLE and SS have anomalous patterns of DNA both 
in serum and in the buff y-coat and that these pat-
terns are typical for each disorder. It is possible 
that understanding the biological signifi cance of 
the diversity in DNA pattern exhibition in white 
blood cells may give new insights into the patho-
physiology of autoimmune disorders. It is also con-
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ceivable that circulating and immune-competent 
cellular DNA markers might off er the promise of 
precise quantitative analysis useful for diagnostic 
purposes, without the need to establish diffi  cult 
cutoff s as is necessary for protein markers (28).
Tumors
As mentioned earlier here, the fi rst signifi cant step 
forward in researching free DNA was made with 
the discovery of increased serum DNA levels in pa-
tients suff ering from diff erent types of tumors, and 
these levels were especially high in patients with 
metastatic tumors. A notable decrease of serum 
DNA levels was observed following radiotherapy 
(2). Since increased free DNA levels are not only 
specifi c for neoplasms and can also be found in 
various infl ammatory conditions (liver cirrhosis, 
hepatitis, systemic lupus erythematosus, rheuma-
toid arthritis), they cannot be considered relevant 
marker of neoplastic process. In 1989, in a tumor 
patient’s plasma, DNA with neoplastic characteris-
tics was found (29). Few years later, two papers 
from 1994 reported that oncogene mutations (in 
K-ras and N-ras genes) were discovered in the plas-
ma and serum of patients with pancreatic cancer, 
myelodisplastic syndrome and acute myeloid leu-
kemia (30,31). The latter studies (29,31), which con-
fi rmed presence of free DNA derived from tumor 
cells in plasma/serum of cancer patients, opened 
up possibilities for detection of more specifi c 
changes regarding the tumor process.
The percentage of free DNA of tumor origin is ex-
tremely variable. According to some authors, its 
amount is 10-90% of total free DNA, whereby the 
highest rates are found in samples with low total 
DNA levels (15). In other studies, free tumor DNA 
share in total free DNA amounted to 0.2-10% (29) 
or 1.9-27% (30).
It is known that tumor cell growth includes genet-
ic and epigenetic changes such as point muta-
tions, chromosomal rearrangements, microsatel-
lite instabilities, promoter region hypermethyla-
tion, mitochondrial DNA mutations, and also the 
presence of some viral DNAs in connection with 
tumor occurrence (HBV, EBV, HCV, HPV). The said 
genetic and epigenetic changes, free DNA concen-
tration changes or viral DNA presence have been 
proven in the last 20 years in various types of can-
cers: pancreatic (32,33), colonic and rectal (10,34-
37), liver (38,39), lung (40,41), head and neck 
(8,9,42,43), nasopharynx (44), ovaries (13), breast 
(45,46), prostate (47,48), testicular (49), leukemia 
(31,50), lymphoma (51,52) etc. The majority of the 
listed studies point to increased free DNA levels in 
cancer patients compared to healthy subjects and 
leaves open the possibility of using free DNA level 
as an early tumor marker. Hopes are built on the 
possibility of detecting tumor-specifi c genome 
changes, particularly if such detection could be 
possible before conventional tumor diagnostics. 
Examples of some tumor-specifi c genetic and epi-
genetic changes that were detected in patient’s 
plasma/serum are presented: N-ras mutations (my-
elodysplastic syndrome, acute myelogenous leu-
kaemia (31)), K-ras mutations (colorectal carcinoma 
(37), pancreatic carcinoma (32)), p53 mutations 
(breast cancer (45), colorectal carcinoma (34)), mu-
tant adenomatous polyposis coli (APC) DNA mole-
cules (colorectal carcinoma (35)), aberrant p16 
methylation (hepatocellular carcinoma (38,39), 
lymphoma (51)), microsatellite alterations (head, 
neck and lung cancer patients (41,42)), EBV DNA 
(nasopharyngeal carcinoma (44)), HPV DNA (head 
and neck squamous cell carcinoma (43)).
Free DNA level changes and the manifestation of 
tumor-specifi c genome changes could be useful 
as treatment success and relapse markers and for 
discriminating responders from non-responders. 
For instance, detecting genetic and epigenetic 
changes in a tumor tissue sample following surgi-
cal intervention and regular examining for the 
presence of such changes in the circulation could 
enable a very early detection of relapse.
The early detection of cancers through analysis of 
circulating DNA could have a substantial impact 
on morbidity and mortality. To achieve this goal, it 
is essential to determine the number of mutant 
molecules present in the circulation of cancer pa-
tients and to develop methods that are suffi  ciently 
sensitive to detect these mutations.
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Transplantation
Microchimerism is the presence of a small quantity 
of foreign cells or foreign DNA in either a tissue or 
circulation of a person. Naturally acquired micro-
chimerism occurs in a two-way transplancental 
trafi c between the mother and fetus while iatro-
genic microchimerism occurs as a consequence of 
a transfusion or transplantation. Free DNA micro-
chimerism in plasma and urine has been described 
over 10 years ago in female patients with a trans-
planted organ from a male donor (4,53).
Kidney transplantation is the most desirable and 
cost-eff ective modality of renal-replacement ther-
apy for patients with irreversible chronic kidney 
failure. Medical causes of early graft dysfunction 
include a broad spectrum of diagnoses, such as 
acute rejection, acute tubular necrosis, drug neph-
rotoxicity and posttransplantation infections. An 
early and adequate diagnosis is very important be-
cause the treatments for some of these patholo-
gies are very diff erent and a mistaken therapeutic 
management can cause an obvious risk to the re-
cipient. Graft loss caused by acute rejection may 
be substantially reduced with better control of the 
adverse immunologic events that occur during the 
early posttransplantation period (5).
In a study conducted in 2002, urine of female re-
cipients with a male graft was examined for the 
presence of Y-chromosome (SRY and DYZ-1) while 
in recipients receiving a HLA mismatched graft the 
HLA-DR gene (DRB1) was examined (54). Results of 
the study showed that presence of donor-specifi c 
DNA in the urine of the recipient is strongly associ-
ated with acute rejection and analysis of DNA de-
rived from donor cells in urine might be an eff ec-
tive and accurate method for the diagnosis of 
acute rejection of a renal transplant. In all patients 
with drug-induced renal dysfunction donor-de-
rived DNA was negative (54).
In a similar study from 2009, authors investigated 
plasma and urine samples from 100 renal trans-
plant recipients obtained during the fi rst 3 months 
after transplantation. Total free DNA and donor 
derived free DNA were analyzed by quantitative 
PCR for the HBB (hemoglobin, beta) and the DYS14 
genes, respectively. Plasma total free DNA concen-
trations increased markedly during acute rejection 
episodes, often before clinical diagnosis, and re-
turned to reference values after antirejection treat-
ment. In this study, cut-off  value for total free DNA 
concentration was established with diagnostic 
sensitivity 89% and specifi city 85%. Although simi-
lar increases were observed during severe post-
transplantation infections, use of the combination 
of total free DNA and procalcitonin (PCT), signifi -
cantly improved the diagnostic specifi city (to 98%; 
95% CI, 92-100%), with 97% of the episodes being 
correctly classifi ed (5).
The same authors performed another study in or-
der to check whether levels of transrenal DNA (Tr-
DNA) are infl uenced by the presence of urinary 
tract infections (UTI). They found out that when 
the Tr-DNA quantifi cation is used as a marker for 
clinical monitoring (i.e. follow up of cancer or trans-
plantation patients), it is important to rule out a 
concomitant UTI, because a secondary cause of in-
creased concentrations of cell free urine DNA could 
confound clinical decisions (55).
Quantitative analysis of a total and transplant spe-
cifi c DNA (Tr-DNA) in urine and/or in plasma of the 
recipient has shown as a good complementary 
marker of a transplant acceptance or rejection and 
it can be helpful in the optimizing of immunosup-
pressive therapy and selective application of a kid-
ney biopsy (5,54,55).
Trauma and sepsis
Knowing the facts that after the severe trauma a 
systemic anti infl ammatory response appears 
which can lead to the organ failure and that after 
the increased cell death result is the increase of 
free DNA level in circulation, Lo et al. have pre-
sumed that in patients with a blunt trauma (56) 
and burns (57) the level of free DNA will be 
changed. They have determined that free DNA in 
those patients is increased depending on the se-
verity of injury and can serve as a prognostic mark-
er for the complication development and the re-
covery length.
A few researchers have studied the changes of free 
DNA concentration in patients in intensive care 
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units (58-62). They have concluded that the level 
of free DNA can serve as a prognostic marker for 
the development of sepsis, organ failure, disease 
severity and mortality.
Acute myocardial infarction (AIM), acute 
stroke and acute mesenteric ischemia 
(AMI)
Elevated level of the cell-free DNA in circulation is 
connected to the cell death whether as a result of 
a tissue injury or as a result of an infl ammatory re-
action. Since the acute myocardial infarction is 
characterized by a combination of necrosis and 
apoptosis of the myocytes, several groups of re-
searchers assumed correctly that in patients with 
AIM level of free DNA in circulation will be elevat-
ed (63-66). Results of the mentioned studies 
showed that level of free DNA in patients with AIM 
is signifi cantly elevated compared to the healthy 
subjects and that it has a potentially diagnostic 
value because patients who have developed com-
plications had higher levels than those with un-
complicated clinical disease course.
Unlike AIM for which there already exist a few very 
good and routinely used biochemical markers, in 
the case of acute stroke such markers do not exist 
in clinical practice. Considering that patophysiolo-
gy of a stroke includes both cell death and blood-
brain barrier dysfunction, a group of researchers 
from Hongkong (67,68) decided to explore the lev-
el of free DNA in plasma of patients with acute 
stroke. Samples have been collected in a period of 
24 hours from the symptom occurrence and re-
sults have shown that plasma DNA concentration 
correlates with the strokes severity and that it can 
serve as a mortality and morbidity predictor even 
in those patients with no visible changes detected 
by neuroimaging techniques.
A group from Spain investigated free plasma DNA 
levels in order to diagnose patients with acute me-
senteric ischemia (AMI) since diagnosing AMI in 
emergency ward is challenging and quite often re-
sults with mortality. They found that plasma DNA 
levels may be a useful biomarker in predicting the 
outcome of patients with AMI (69).
Acute pancreatitis (AP)
Only two research groups have investigated level 
of free DNA in circulation in patients with the acute 
pancreatitis. In the paper from 2006, authors have 
shown that the level of free plasma DNA (on the 
day of admittance and on the fi fth day after the 
admittance) is lower in patients with severe acute 
pancreatitis compared to control subjects and that 
it is not possible to diff er, by the plasma DNA level, 
mild from severe illness form (70). In a study pub-
lished in 2009, authors have shown that the free 
serum DNA level on the fi rst and fourth day after 
hospitalization is signifi cantly elevated in those 
patients who will develop severe form of pancrea-
titis and that free serum DNA correlates with the 
pancreatic necrosis level (71). The reason for this 
disagreement could be diff erent study design 
(number of participants, number and time of sam-
ples per subject, participant’s clinical status) and 
diff erence in tissue examined (plasma vs. serum). 
The most recent study from the second group (72) 
demonstrate that cell-free DNA measured in both 
plasma and serum of patients with AP on the fi rst 
day after hospital admission is signifi cantly higher 
in patients who developed severe pancreatitis 
than in those with mild disease. Both plasma and 
serum levels of free DNA predict severity of AP 
better than other common markers and scoring 
systems, but another great value of this new mark-
er is that it predicts disease severity on the fi rst day 
after hospitalization and enables timely admission 
to Intensive Care Units (72).
Non-invasive prenatal diagnosis
Notwithstanding their routine application for the 
past 30 years, modern invasive prenatal diagnostic 
techniques (such as amniocentesis and chorionic 
villus sampling) carry a certain risk for the mother 
and the fetus. The discovery of fetal DNA in mater-
nal blood plasma and serum opened up possibili-
ties for development of non-invasive prenatal di-
agnostic methods (3). Further breakthroughs re-
vealed its benefi ts, such as rapid clearance after 
delivery (20), detectability from 5th week of gesta-
tion (73) and easy accessibility (compared to inva-
sive sampling), but also some disadvantages: prac-
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tically inseparable from maternal free DNA, per-
centage of free fetal DNA in total free DNA 
amounts to only 5-10%, depending on week of 
gestation (74). It originates from syncytiotropho-
blast (75) and it was proven to be shorter, more 
degraded and more hypomethylated compared 
to maternal free DNA. The presence of free fetal 
DNA was proven also in other maternal bodily fl u-
ids such as amniotic fl uid, urine, liquor and perito-
neal fl uid (74).
Considering that, at the moment, it is technically 
impossible to separate maternal from fetal free 
DNA and considering that maternal free DNA in-
terferes with fetal DNA analysis, robust detection 
and quantifi cation have been achieved when the 
fetal DNA sequence of interest does not have a 
maternal counterpart (e.g., Y chromosomal DNA, 
RhD gene when the mother is RhD negative) by 
techniques such as real-time polymerase chain re-
action (PCR) (76,77).
The fi rst application of free circulating fetal DNA 
was for the purpose of non-invasive detection of 
fetal sex. The commonly used markers are SRY, 
amelogenin, DYS14; the analysis is reliable from 7th 
week of gestation, and is applied in cases where X-
linked diseases is suspected to avoid amniocente-
sis in case of female fetus, in case of ultrasound-
detected indistinguishable or ambiguous sex or-
gans to determine genetic sex and in case of con-
genital adrenal hyperplasia so that if fetus is a 
male, dexamethasone therapy can be avoided (76). 
This analysis is routinely applied in several Europe-
an countries. In United Kigdom, for example, sig-
nifi cant decrease (45%) in a number of invasive 
tests performed is noted as a consequence of im-
plementation of early noninvasive prenatal fetal 
sex diagnosis (77).
Other than for the purpose of fetal sex determina-
tion, free circulating fetal DNA is typically used for 
determining fetal RhD status in RhD negative 
mothers (78-80) to avoid non-selective antenatal 
immunoprophylaxis.
Measuring free fetal DNA concentration in mater-
nal plasma is the third most common use of free 
fetal plasma DNA. It is done by measuring quantity 
of DNA sequences from Y chromosome. Namely, it 
has been established that its concentration in vari-
ous forms of pathological pregnancies (preterm 
labour (81), fetal aneuploidy (82), idiopathic poly-
hydramnios (83), fetal growth restriction (84), 
preeclampsia (85), fetal-maternal hemorrhage (86), 
invasive placenta (87)) is increased so it is investi-
gated as a potential pregnancy pathology marker.
Recently, new universal marker for fetal DNA is dis-
covered and is readily detectable in maternal plas-
ma: hypermethylated RASSF1A. When applied to 
prenatal RhD genotyping, this marker allows the 
detection of false-negative results caused by low 
fetal DNA concentrations in maternal plasma. Hy-
permethylated RASSF1A marker can also be ap-
plied to many other prenatal diagnostic and moni-
toring scenarios (88).
Since detection of subtle fetal mutations is diffi  cult 
due to the overwhelming maternal DNA back-
ground, possibilities for non-invasive prenatal fetal 
DNA analysis for various monogenic diseases are 
limited to paternally inherited or de novo muta-
tions. Until today a few cases of prenatal non-inva-
sive diagnosis of monogenic diseases have been 
published: ß-thalassemia major (89), myotonic dys-
trophies (90), achondroplasia (91), Huntington dis-
ease (92) and cystic fi brosis (93).
One of the newest applications of free fetal DNA in 
diagnostics is described in a recently published 
study. This study demonstrates the fi rst validated 
non-invasive cell-free fetal DNA fi ngerprinting 
method which predicts both gender and which 
embryo implanted at 9 weeks gestation following 
multiple embryo transfer (94).
The discovery of the presence of tumor and donor 
transrenal DNA focused fetal DNA research in the 
direction of fetal DNA detection in maternal urine, 
but the study results were contradictory for a long 
period of time (95). It was not until a recent study, 
where the size of amplifi ed regions was signifi -
cantly reduced (96) that the sensitivity of fetal DNA 
detection in maternal urine improved.
Since fetal DNA concentration is extremely low, Lo 
et al. detected it in 1997 by using the nested PCR 
method. With the occurrence of real time PCR in-
struments, the sensitivity, rapidity and robustness 
of fetal DNA detection increased.
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More recently, new attempts to incorporate mass 
spectrometric techniques to develop accurate and 
highly sensitive high-throughput clinical diagnos-
tic tests have been reported (97).
Present fetal DNA studies are based on three basic 
experimental approaches: enriching free fetal DNA 
fraction in plasma (98); detecting fetal-specifi c epi-
genetic markers or placenta-specifi c mRNA mark-
ers (99-101); developing precise digital PCR 
(102,103) and second-generation genetic sequenc-
ing (104-109).
Other possible applications
Research conducted in 1993 set the level of the 
plasma DNA as in vivo marker of the cell death in 
patients older than 68 years of age (110). The high-
est DNA level was determined in a group of senior 
subjects with some acute or chronic disease 
(among them a rate of survival after one month 
was lower), lower in a group of senior subjects with 
good health and the lowest level of free DNA was 
determined in a control group constituted of mid-
dle aged subjects.
Level of free plasma DNA was also examined in fe-
male patients with endometriosis (111); signifi cant-
ly higher level was determined within the diseased 
subjects than within the healthy ones. This result is 
in concordance with the pathophysiological pro-
cess behind the endometriosis since it is one of the 
most common benign gynecological prolifera-
tions with infl ammatory activation in premeno-
pausal women.
A signifi cantly lower level of free plasma DNA was 
found in patients with Parkinson disease (112) but 
it is not determined that it represents a confi dent 
marker of the disease progression.
In a recently published paper from India, authors 
managed to distinguish between ataxia patients 
(Friedreich’s Ataxia and Spinocerebellar Ataxia 
Types 2 and 12) and healthy controls using free 
plasma DNA concentration. They hypothesised 
that signifi cantly higher concentration of plasma 
DNA appears to be due to neuronal and muscular 
degeneration in these patients (113).
A group from Shangai performed quantifi cation of 
circulating cell-free DNA in the serum of patients 
with obstructive sleep apnea-hypopnea syndrome 
(OSAHS). They found that the increasing concen-
tration of serum DNA in patients with OSAHS was 
positively correlated with disease severity. Acoord-
ing to them, serum DNA may become an impor-
tant parameter for monitoring the severity of OSA-
HS and eff ectiveness of therapy (114).
One of the research grups tried to investigate the 
acute eff ects of a single bout of high-intensive 
strength training on the production of cell-free 
plasma DNA (cf-DNA). These results indicate that, cf-
DNA (and oxypurines) might be relevant biomarkers 
for cellular damage, mechanical, energetic, and/or 
ischemic stress in context with exercise (115).
Besides the level (concentration) measurement 
and the presence of the specifi c free human DNA 
in circulation it is also possible to detect the free 
parasitic DNA. That is useful because, in some clin-
ical stages of the disease, it is diffi  cult to detect 
parasitic infection (schistosomiasis) (116).
Discussion and conclusion
In the past decade, cell free DNA, or circulating cell 
free DNA, or cell free circulating DNA, isolated 
from body fl uids such as plasma/serum/urine has 
emerged as an important tool for clinical diagnos-
tics. The molecular biology of circulating cell free 
DNA is not completely understood but there is 
currently an increased eff ort to understand the or-
igin, mechanism of its circulation and sensitive 
characterization for the development of diagnos-
tic applications. There has been considerable 
progress towards these goals using real-time 
polymerase chain reaction technique. More re-
cently, new attempts to incorporate mass spectro-
metric techniques to develop accurate and highly 
sensitive high-throughput clinical diagnostic tests 
have been reported (Table 1).
Aim of this brief overview was to present various 
clinical fi elds and pathological states in which 
analysis of free DNA could be of interest (Table 2). 
Just by browsing at the quantity of published sci-
entifi c papers on the topic of free DNA it is easy to 
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Method Application
Nested PCR (3,56) Non-invasive sex determination
Real time PCR (4,5,20,25,38,68,75,76,81)
Non-invasive sex and RhD status determination;
Quantifi cation of total/fetal free DNA;
Detection and quantifi cation of mutations
Microsatellite markers analysis (41,42,50) Loss of heterozigosity
Diff erential DNA methylation between fetus and mother / 
methylation-specifi c PCR (38,90,100)
Detection of fetal-derived maternally inherited alleles;
Detection of aberrant methylation
Epigenetic-genetic chromosome dosage approach (101) Trisomy 21 detection
Plasma placental RNA allelic ratio (102) Aneuploidy detection
Digital size selection and relative mutation dosage on DNA (103) Monogenic diseases
Shotgun sequencing DNA (104) Aneuploidy detection
Massively parallel genomic sequencing of DNA (105-109) Aneuploidy detection
Mass spectrometry (97) Monogenic diseases
TABLE 1. Methods used for free DNA analysis.
Pathological / psychological 
state
Qualitative and quantitative 






Increased free DNA level;
Anomalous patterns of DNA 
typical for each disorder
Leon SA et al. (1977)
Leon SA et al. (1981)
Tan EM et al. (1966)
Raptis L et al. (1980)
Amoura Z et al. (1997)
Atamaniuk J et al. (2011)
Mosca M et al. (2009)
Bartoloni E et al. (2011)
Galeazzi M et al. (2003)
Tumors
Increased free DNA level;
Tumor DNA specifi c genetic and 
epigenetic changes
Leon SA et al. (1977)
Jiang WW et al. (2006)
Jiang WW et al. (2005)




Increased donor free DNA level;
Increased recipient free DNA level
Zhang J et al. (1999)
Garcia Morreira V et al. (2009)
Garcia Morreira M et al. (2009)
Lo YM et al. (1998)




Increased free DNA level
Lo YMD et al. (2000)
Chiu TW et al. (2006)
Wijeratne S et al. (2004)
Rhodes A et al. (2006)
Saukonnen K et al. (2007)






Increased free DNA level
Chang CP et al. (2003)
Antonatos D et al. (2006)
Rainer TH et al. (2006)
Destouni A et al. (2009)
Rainer TH et al. (2003)
Lam NY et al. (2006)
Arnalich F et al. (2010)
Bagul A et al. (2006)
Gornik I et al. (2009)
Gornik O et al. (2011)
Pregnancy
Increased free fetal DNA level;
Increased free total DNA level;
Fetal DNA specifi c changes
Lo YMD et al. (1997) Lo YMD et al. (1999)73-109*
*refers to the reference numbers
TABLE 2. Qualitative and quantitative changes of free DNA in diff erent pathological states
conclude that researchers and clinicians show (and 
share) a great interest for this scientifi c fi eld. Be-
cause of that, one can expect that this analyte will 
soon became part of the routine clinical care and 
management of the patient. In order for this to 
happen, few important issues need to be solved.
The fi rst encountered problem when comparing 
and evaluating results of various studies is the 
Biochemia Medica 2012;22(1):24–38
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non-standardization of the methods used. Diff er-
ent groups have used diff erent methods for DNA 
isolation, quantifi cation and detection, with each 
of them having its sensitivity and specifi city. For 
example, previously used methods for DNA detec-
tion had a signifi cantly lower sensitivity compared 
to nowadays broadly spread real time PCR. Nowa-
days, the majority of researchers use commercially 
available columns for DNA isolation based on the 
ion exchange process of binding DNA. And even 
when the same extraction method was used, start-
ing sample volumes and volume of the elution 
buff ers were diff erent.
Second issue is preanalytical: the non-existence of 
consensus on the preferred tissue for analysis (se-
rum vs. plasma) and on the centrifugation speed 
during the serum/plasma separation. In the early 
years of free DNA research, serum was more favor-
able compared to plasma. Nowadays, plasma DNA 
analysis is more common and more widespread, 
mainly because in that way it is possible to avoid 
false higher free DNA values which are result of 
cell degradation during the process of clot forma-
tion.
Except for the sample type and centrifugation pro-
tocol, sample collecting tubes are also important 
because they can signifi cantly infl uence free DNA 
yield (117). When samples can be processed within 
eight hours of blood draw, K3EDTA tubes can be 
used. Prolonged transfer times in K3EDTA tubes 
should be avoided as the proportion of fetal DNA 
present decreases signifi cantly; in these situations 
the use of cell stabilising tubes is preferable.
Third problem is the use of diff erent standards for 
free DNA quantifi cation, commercially available or 
prepared in house. Consecutively, quantitative 
analysis results have been expressed in two ways: 
in ge/mL (ge = genome equivalent) or in ng/mL. 
Although those units could be mutually converted 
by use of the conversion factor of one diploid ge-
nome being equivalent to 6.6 pg of DNA (118), it 
additionally complicates the comparison of results 
from diff erent studies.
One should be aware that data obtained as a re-
sult of quantitative analysis of the complete free 
DNA is extremely nonspecifi c because elevated 
free DNA level has been noted in diff erent patho-
logical states (infl ammation, autoimmune process, 
diff erent acute states, malignancy etc.) which 
sometimes do not exclude one another, especially 
because not even the mechanism of origin nor 
free DNA elimination has been completely clari-
fi ed. Interestingly, only few researchers have con-
sidered the infl uence of liver and kidney insuffi  -
ciency on the quantity of free DNA, which could 
have the most signifi cant infl uence on patients 
with severe sepsis, trauma or organ failure (pa-
tients in Intensive care units). So, application of 
quantitative DNA analysis in acute states for diag-
nostic purposes will hardly become part of the 
routine practice for two main reasons: nespecifi ci-
ty of the results and length of the analysis (2-3 
hours). However, this result could serve as an ex-
cellent prognostic marker.
In the fi eld of free tumor DNA, its value is rarely 
correlated with the value of the other tumor mark-
ers. In order for analysis of genetic and epigenetic 
changes to serve in the early tumor detection, it is 
necessary to be very familiar with the genome 
changes specifi c for a certain type and localization 
of the tumor because those already known are of-
ten characteristic for diff erent types of tumors.
According to the latest research, application of 
DNA analysis in transplant patients has a great po-
tential for utilization in the clinical laboratory. In 
fact, today’s markers of rejection of a kidney trans-
plant (urea and creatinine) are not particularly sen-
sitive and biopsy, even though a ‘’golden standard’’, 
is a diagnostic procedure which should be applied 
selectively. Measurement of free DNA in transplant 
patients in certain time intervals (with a marker like 
procalcitonin for diff erential diagnostic exclusion of 
patients with urinary infection (55)) would be useful 
for monitoring the state of the kidney transplant as 
well as the selective biopsy application.
Although free DNA research is being done for 
many years, progress in a diagnostic sense is not 
going according to the plan. One reason for slow 
utilization of this potential new clinical marker is 
that majority of the research was done on a smaller 
number of subjects (20-70), rarely over 200, and so 
far there were only few large clinical and multicenter 
studies (106-109). Therefore the power of statistical 
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tests used in the analysis is questionable as well as 
the conclusions brought on the basis of it.
In addition, reference intervals for the healthy pop-
ulation are still not available. Since the creation of 
reference intervals requires careful planning, mon-
itoring and documentation of every aspect of the 
study and characterization of variations attribut-
able to the pre-analytical and analytical factors, 
only future large studies can provide data for es-
tablishing them (119).
Undoubtedly, the greatest progress has been 
achieved in the fi eld of non invasive prenatal diag-
nosis (NIPD). While in some other diagnostic fi elds, 
analysis of free DNA is done exclusively in research 
institutions, free DNA analysis for the purpose of 
non invasive sex determination and fetal RhD sta-
tus determination is conducted as a routine prac-
tice in some EU countries (77,80).
Due to the technical impossibility of separating 
maternal from fetal DNA, application of free fetal 
DNA analysis has its limitations: non existence of 
the positive control for extraction and amplifi ca-
tion of fetal DNA, analysis is limited by fetal gender 
and knowing of the parental genotypes, it is pos-
sible to detect only those mutations which are pa-
rentally inherited or occurred de novo.
As mentioned earlier, a new test for the detection 
of fetal DNA in maternal plasma was developed; it 
is based on the detection of a hypermethylated 
placental (fetal) DNA sequence in the maternal cir-
culation. In contrast to existing fetal DNA markers 
that detect Y-chromosomal sequences and genet-
ic variations between the fetus and mother, this 
marker (RASSF1A promoter) is applicable to all 
pregnancies irrespective of the sex and genetic 
variations of the fetus (88).
During the last three years the development of 
digital PCR and second generation genetic se-
quencing (103,104), analytical techniques which 
enable non invasive prenatal diagnosis of aneu-
ploidy, has overcome these limitations. These tech-
niques enable measurement of relative amount of 
free DNA from chromosome 21 (direct measure-
ment of total number of copies from chromosome 
21 according to the referral chromosome) in such a 
way that it is possible to estimate number of chro-
mosomes 21 (or any other) in a sample that con-
tains fetal DNA (Table 1).
The advent of massively parallel sequencing has 
given us a quantitative and powerful tool for stud-
ying circulating DNA on a genome-wide level (120). 
Using this approach, fetal chromosomal aneuploi-
dies can be robustly detected using maternal plas-
ma. Furthermore, a genome-wide genetic map of 
a fetus can also be constructed using this approach 
(120). This method has also allowed one to identify 
tumor-associated chromosomal translocations, 
which can then be detected in plasma. Current de-
fi ciencies of these methods are their expensive-
ness, longevity and analysis complexity, however, 
with the further technological progress all of these 
disadvantages should be overcomed and non in-
vasive prenatal detection of most common aneu-
ploidy enabled.
As cell-free fetal DNA testing continues to be de-
veloped and translated, signifi cant ethical, legal 
and social questions will arise that will need to be 
addressed by those with a stake in the use of this 
technology. Since non-invasive prenatal diagnosis 
is likely to be introduced in the near future, this will 
raise important ethical questions concerning 
meaningful reproductive choice, the autonomy 
rights of future children, equity of access and the 
proportionality of testing. It will probably be easier 
to get cell-free fetal DNA testing for chromosomal 
abnormalities and single-gene disorders, but cau-
tion should be taken with respect to determina-
tion of sex and behavioral or late-onset condi-
tions.
Despite all of the earlier denominated issues, free 
DNA research is continuing in the form of the large 
scale clinical studies which would at the end eval-
uate its potential application as new analyte in 
clinical laboratory diagnostics. My personal favor-
ite is fi eld of non-invasive prenatal diagnosis, 
where the breakthrough will be the biggest and 
will lead to abandoning invasive methods in pre-
natal diagnostics.
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Slobodna DNA – novi potencijalni analit u kliničkoj laboratorijskoj 
dijagnostici?
Sažetak
Postojanje slobodne DNA (engl. cell free DNA) u cirkulaciji čovjeka poznato je još od pedesetih godina prošlog stoljeća, međutim, intenzivnija 
istraživanja u ovom području provode se tek posljednjih desetak godina. Ovaj pregledni članak donosi kratak osvrt na dosadašnja istraživanja 
slobodne DNA u različitim kliničkim područjima i patološkim stanjima te razmatra mogućnosti primjene novog potencijalnog analita u kliničkoj 
laboratorijskoj dijagnostici.
Analiza slobodne DNA najčešće se primjenjuje u području neinvazivne prenatalne dijagnostike u svrhu određivanja spola ili RhD statusa ploda. 
Posljednja otkrića epigenetskih promjena DNA posteljice/ploda i detekcija RNA specifi čne za posteljicu/plod, omogućile su primjenu ove tehnolo-
gije kod svih trudnoća, neovisno o spolu ploda. Primjenom novih tehnika kao što su sekvencioniranje druge generacije, digitalna lančana reakcija 
polimerazom i masena spektrometrija, moguće je otkriti već i vrlo male količine specifi čne DNA u prisutnosti velike količine preostalih nespecifi -
čnih nukleinskih kiselina. 
Druga najvjerojatnija mogućnost primjene ovog analita je u području onkologije gdje je otkrivanje i praćenje tumora omogućeno otkrićem nukle-
inskih kiselina porijeklom iz stanica tumora.
Treće potencijalno područje primjene ovog analita jest transplantacijska medicina gdje bi koncentracija slobodne DNA mogla biti biljeg odbaci-
vanja transplantata.
Prije bilo koje daljnje primjene ovog biološkog biljega, potrebno je standardizirati prijeanalitičke i analitičke postupke u analizi slobodne DNA. U 
području neinvazivne prenatalne dijagnostike pojavit će se važna etička, pravna i sociološka pitanja na koja će trebati odgovoriti.
Ključne riječi: slobodna DNA; slobodna fetalna DNA; DNA u plazmi; neinvazivna prenatalna dijagnostika; klinička laboratorijska dijagnostika; 
analiza određivanja spola
